澳华内镜(688212) - 2024年6月24日投资者关系活动记录表

Product Development and Feedback - AQ-300 product received positive clinical feedback, with high praise for image clarity, color accuracy, and operability [1] - The company continuously optimizes product performance based on clinical feedback to provide precise and reliable operation experiences [2] Market and Industry Trends - The soft endoscopy market is driven by increasing clinical diagnostic needs and rising early cancer screening rates [2] - Hospital demand for new and replacement soft endoscopy equipment is growing due to increased diagnostic requirements [2] Financial and Operational Strategies - The company conducted two rounds of equity incentives in 2022 and 2023, leading to increased share-based payment expenses in 2024 [2] - The sales team and distributors are stable and experienced, actively working to explore market potential through refined marketing management [2] Academic and Industry Engagement - The company actively participates in industry conferences and engages with experts to discuss innovation, clinical practices, and technological developments [3] - Successful events like the "Aohua Cup" CBI National Case Competition and hands-on training sessions have provided learning opportunities and showcased product advantages [3]